View More View Less
  • 1 Szent Pantaleon Kórház – Rendelőintézet Dunaújváros, 2400 Dunaújváros, Korányi Sándor u. 4–6.
  • | 2 Szent Pantaleon Kórház – Rendelőintézet Dunaújváros, Dunaújváros
  • | 3 Szent Pantaleon Kórház – Rendelőintézet Dunaújváros, Dunaújváros
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $356.00

Absztrakt:

Esetismertetés: A szerzők egy 78 éves hölgybeteg esetét mutatják be, aki tizenévesként részesült gyógyszeres kezelésben pulmonális tbc miatt, majd a 2015-ben IBD kezelése céljából indított biológiai terápia kapcsán nemcsak légzőszervi tünetei lángoltak fel kb. 60 év tünetmentességet követően, hanem akut has klinikai képe is kialakult. Sürgős műtétre vittük a beteget, ahol vékonybél perforatio miatt segmentresectio történt, a szövettani vizsgálat enterális tbc-t igazolt. A posztoperatív szakban indított gátlószeres kezelés hatására a beteg tünet- és panaszmentessé vált. Megbeszélés: A tuberculosis egy életet veszélyeztető megbetegedés, amely lényegében bármely szervet érintheti. Ezen cikkünkkel szeretnénk felhívni a figyelmet biológiai terápiák, ill. a különböző immunmoduláns kezelések potenciálisan fatális mellékhatásaira és a társszakmák közötti hatékony együttműködés fontosságára.

  • 1

    Holloway KL, Henneberg RJ, de Barros Lopes M, Henneberg M. Evolution of human tuberculosis: A systematic review and meta-analysis of paleopathological evidence. Homo. 2011 Dec; 62(6): 402–458.

  • 2

    Comas I, Coscolla M, Luo T, Borrell S, Holt KE, Kato‑ Maeda M, Parkhill J, Malla B, Berg S, Thwaites G, et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat Genet. 2013 Oct; 45(10): 1176–1182.

  • 3

    Escalante P. In the clinic. Tuberculosis. Ann Intern Med. 2009 Jun 2; 150(11): ITC61-614; quiz ITV616.

  • 4

    Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006 May 27; 367(9524): 1747–1757.

  • 5

    Miller TL, McNabb SJ, Hilsenrath P, Pasipanodya J, Weis SE. Personal and societal health quality lost to tuberculosis. PLoSOne. 2009; 4(4): e5080.

  • 6

    Chee CBE, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: Opportunities and challenges. Respirology 2018 Jun 14. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 7

    WHO Global Tuberculosis Report 2017. (http://www.who.int/tb/publications/global_report/en/)

  • 8

    Centers for Disease Control and Prevention – Tuberculosis Data and Statistics (https://www.cdc.gov/tb/statistics/default.htm)

  • 9

    Wang H, Dwyer-Lindgren L, Lofgren KT, Rajaratnam JK, Marcus JR, Levin-Rector A, Levitz CE, Lopez AD, Murray CJ. Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012 Dec 15; 380 (9859): 2071–2094.

  • 10

    Korányi Bulletin 2018. (http://www.koranyi.hu/tartalom/bulletin/Evkonyv2018.pdf)

  • 11

    Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009 Dec; 7(12): 845–855.

  • 12

    Zhang Y, Yew WW, Barer MR. Targeting persisters for tuberculosis control. Antimicrob Agents Chemother. 2012 May; 56(5): 2223–2230.

  • 13

    Zhang Y. Persistent and dormant tubercle bacilli and latent tuberculosis. Front Biosci. 2004 May 1; 9: 1136–1156.

  • 14

    Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update. Respirology 2010 May; 15(4): 603–622.

  • 15

    Wang KY, Lin YS, Sy CL, Huang WC, Chen LW. Hyperbaric oxygen therapy increases the risk of tuberculosis disease. Int J Tuberc Lung Dis. 2018 Jun 1; 22(6): 637–640.

  • 16

    Lin PL, Plessner HL, Voitenok NN, Flynn JL. Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc. 2007 May; 12(1): 22–25.

  • 17

    Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001; 345: 1098–1104.

  • 18

    Nunez Martinez O, Ripoll Noiseux C, Carneros Martin JA, Gonzalez Lara V, Gregorio Maranon HG. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am J Gastroenterol. 2001; 96: 1665–1666.

  • 19

    Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010 Nov; 36(5): 1185–1206.

  • 20

    Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010 Apr; 24(2): 167–182.

  • 21

    Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev. 2008; 8(2): 147–152.

  • 22

    Dave M, Purohit T, Razonable R, Loftus EV Jr. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis. 2014 Jan; 20(1): 196–212.

  • 23

    Cohn HM, Dave M, Loftus EV Jr. Understanding the cautions and contraindications of immunomodulator and biologic therapies for use in inflammatory bowel disease. Inflamm Bowel Dis. 2017 Aug; 23(8): 1301–1315.

  • 24

    Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, Wilkinson KA, Banchereau R, Skinner J, Wilkinson RJ, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010 Aug 19; 466(7309): 973–977.

  • 25

    Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. Lancet Respir Med. 2016 Mar; 4(3): 213–224.

  • 26

    Lu C, Wu J, Wang H, Wang S, Diao N, Wang F, Gao Y, Chen J, Shao L, Weng X, et al. Novel biomarkers distinguishing active tuberculosis from latent infection identified by gene expression profile of peripheral blood mononuclear cells. PLoSOne. 2011; 6(8): e24290.

  • 27

    Verhagen LM, Zomer A, Maes M, Villalba JA, Del Nogal B, Eleveld M, van Hijum SA, de Waard JH, Hermans PW. A predictive signature gene set for discriminating active from latent tuberculosis in Warao Amerindian children. BMC Genomics 2013 Feb 1; 14: 74.

  • 28

    Pan L, Wei N, Jia H, Gao M, Chen X, Wei R, Sun Q, Gu S, Du B, Xing A, et al. Genome-wide transcriptional profiling identifies potential signatures in discriminating active tuberculosis from latent infection. Oncotarget 2017 Dec 4; 8(68): 112907–112916.

  • 29

    Sharma MP, Bhatia V. Abdominal tuberculosis. Indian J Med Res. 2004 Oct; 120(4): 305–315.

  • 30

    Uma Debi, Vasudevan Ravisankar, Kaushal Kishor Prasad, Saroj Kant Sinha, Arun Kumar Sharma. Abdominal tuberculosis of the gastrointestinal tract: Revisited. World J Gastroenterol. 2014 Oct 28; 20(40): 14831–14840.

  • 31

    Ara C, Sogutlu G, Yildiz R, Kocak O, Isik B, Yilmaz S, Kirimlioglu V. Spontaneous small bowel perforations due to intestinal tuberculosis should not be repaired by simple closure. J Gastrointest Surg. 2005 Apr; 9(4): 514–517.

Submit Your Manuscript

 

The author instruction is available in PDF.
Please, download the file from HERE

 

Senior editors

Editor(s)-in-Chief: Oláh, Attila

Editorial Board

  • DR. BÁLINT ANDRÁS
  • DR. BEZSILLA JÁNOS
  • DR. BOROS MIHÁLY
  • DR. BURSICS ATTILA
  • DR. DAMJANOVICH LÁSZLÓ
  • DR. ENTZ LÁSZLÓ
  • DR. GULYÁS GUSZTÁV
  • DR. HARSÁNYI LÁSZLÓ
  • DR. HORVÁTH ÖRS PÉTER
  • DR. ISTVÁN GÁBOR
  • DR. KECSKÉS LÁSZLÓ
  • DR. KÓBORI LÁSZLÓ
  • DR. KUPCSULIK PÉTER
  • DR. LÁZÁR GYÖRGY
  • DR. LESTÁR BÉLA
  • DR. MÁTRAI ZOLTÁN
  • DR. MOHOS ELEMÉR
  • DR. MOLNÁR F. TAMÁS
  • DR. ONDREJKA PÁL
  • DR. PAPP ANDRÁS
  • DR. RÉNYI-VÁMOS FERENC
  • DR. ROMICS LÁSZLÓ JR.
  • DR. SÓTONYI PÉTER
  • DR. SZIJÁRTÓ ATTILA
  • DR. SZŰCS ÁKOS
  • DR. VEREBÉLY TIBOR
  • DR. VERECZKEI ANDRÁS

Petz Aladár County Teaching Hospital, Surgery
Vasvári Pál út 2. H-9024 Győr, Hungary
Phone: +36 96 503 320 --- Fax: +36 96 507 936
E-mail: olaha@petz.gyor.hu

Indexing and Abstracting Services:

  • Index Medicus
  • PubMed Central

 

2020  
CrossRef Documents 37
WoS Cites 45
Wos H-index 8
Days from submission to acceptance 60
Days from acceptance to publication 63

 

2019  
WoS
Cites
63
CrossRef
Documents
31

 

Magyar Sebészet
Publication Model Hybrid
Submission Fee none
Article Processing Charge 900 EUR/article
Printed Color Illustrations 40 EUR (or 10 000 HUF) + VAT / piece
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription Information Online subsscription: 276 EUR / 372 USD
Print + online subscription: 320 EUR / 440 USD
Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Magyar Sebészet
Language Hungarian
Size B5
Year of
Foundation
1947
Publication
Programme
2021 Volume 74
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Sebész Társaság -- Hungarian Surgical Society
Founder's
Address
H-1082 Budapest, Hungary Üllői út 78.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 0025-0295 (Print)
ISSN 1789-4301 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Feb 2021 16 0 0
Mar 2021 20 1 1
Apr 2021 22 2 7
May 2021 14 0 0
Jun 2021 11 0 0
Jul 2021 10 1 1
Aug 2021 0 0 0